Δ9-四氢大麻酚升高健康人纹状体谷氨酸水平:与精神病样效应相关
该双盲随机安慰剂对照交叉设计研究纳入16名既往大麻暴露有限健康人,发现静脉Δ9-THC(1.19 mg/2 ml)较安慰剂显著升高左侧尾状核头Glx(P=0.027)。出现短暂精神病样症状者基线Glx更低且Δ9-THC后升幅更高,基线Glx低和既往大麻暴露多与升幅大相关。
要点
- Δ9-THC急性升高健康人左侧尾状核头谷氨酸复合物水平。
- 出现精神病样症状者基线Glx更低、Δ9-THC后升幅更高。
- 基线Glx低和既往大麻暴露多与Δ9-THC诱导Glx升幅大相关。
核心结论
- 纹状体谷氨酸水平升高可能介导急性大麻诱导的精神病样效应。
- 较低基线谷氨酸水平可能是对Δ9-THC急性精神病样效应更敏感的标记。
研究设计与样本
- 双盲、随机、安慰剂对照、交叉设计。
- 16名健康参与者(7名男性),既往大麻暴露有限。
- 静脉给予Δ9-THC 1.19 mg/2 ml,用质子磁共振波谱测量纹状体谷氨酸。
主要发现
- 与安慰剂相比,急性Δ9-THC显著升高左侧尾状核头Glx(P=0.027)。
- 约70%样本出现短暂精神病样症状,其基线Glx显著低于无此症状者(安慰剂;P=0.023)。
- 出现精神病样症状者Δ9-THC后Glx升幅为无此症状者的2.27倍。
- 较低基线Glx值与更高Δ9-THC诱导Glx升幅相关(r=-0.55;P=0.026)。
- 更高既往大麻暴露与更高Δ9-THC诱导Glx升幅相关(r=0.52;P=0.040)。
临床怎么用
- 提示纹状体谷氨酸可作为大麻相关精神病样效应的潜在生物标记。
- 基线谷氨酸较低者可能对Δ9-THC急性精神病样效应更敏感。
局限性
- 样本量小(16名健康参与者,7名男性),既往大麻暴露有限。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The neurobiological mechanisms underlying the association between cannabis use and acute or long-lasting psychosis are not completely understood. While some evidence suggests altered striatal dopamine may underlie the association, direct evidence that cannabis use affects either acute or chronic striatal dopamine is inconclusive. In contrast, pre-clinical research suggests that cannabis may affect dopamine via modulation of glutamate signaling. A double-blind, randomized, placebo-controlled, crossover design was used to investigate whether altered striatal glutamate, as measured using proton magnetic resonance spectroscopy, underlies the acute psychotomimetic effects of intravenously administered delta-9-tetrahydrocannabinol (Δ9-THC; 1.19 mg/2 ml), the key psychoactive ingredient in cannabis, in a set of 16 healthy participants (7 males) with modest previous cannabis exposure. Compared to placebo, acute administration of Δ9-THC significantly increased Glutamate (Glu) + Glutamine (Gln) metabolites (Glx) in the left caudate head (P = 0.027). Furthermore, compared to individuals who were not sensitive to the psychotomimetic effects of Δ9-THC, individuals who developed transient psychotic-like symptoms (~70% of the sample) had significantly lower baseline Glx (placebo; P 7= 0.023) and a 2.27-times higher increase following Δ9-THC administration. Lower baseline Glx values (r = -0.55; P = 0.026) and higher previous cannabis exposure (r = 0.52; P = 0.040) were associated with a higher Δ9-THC-induced Glx increase. These results suggest that an increase in striatal glutamate levels may underlie acute cannabis-induced psychosis while lower baseline levels may be a marker of greater sensitivity to its acute psychotomimetic effects and may have important public health implications.
引用
- Colizzi M, Weltens N, McGuire P, et al. Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis. Mol Psychiatry. 2019. PMID: 30770892. doi:10.1038/s41380-019-0374-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。